⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386463 | 0.92 | — | — | |
| SCHEMBL7628906 | 0.90 | OPRM1 (0.44) | — | |
| SCHEMBL383851 | 0.90 | OPRM1 (0.44) | — | |
| SCHEMBL387860 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL29678590 | 0.77 | DNM1 (0.41) | — | |
| SCHEMBL12475283 | 0.74 | — | — | |
| SCHEMBL4170717 | 0.74 | — | — | |
| SCHEMBL1343853 | 0.72 | — | — | |
| SCHEMBL9368619 | 0.72 | — | — | |
| SCHEMBL270381 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126606-B | Method for dispersing a biofilm comprising gram-negative bacteria | Q生物股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3986394-A1 | BIOFILM DISRUPTION | QBiotics Pty Ltd (AU) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020252535-A1 | BIOFILM DISRUPTION | QBiotics Pty Ltd (AU) | 2020-12-24 | — | — | WO | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8044056-B2 | Adenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-4975538-A | MICROBIOCIDES AND BETA-LACTAMASE INHIBITORS | THE UPJOHN COMPANY (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0368908-A1 | THERAPEUTICALLY USEFUL $g(b)-LACTAMS | THE UPJOHN COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0357604-A1 | ANTIBIOTIC BETA-LACTAMS CONTAINING A PYRIDONE CARBOXYLIC ACID OR ACID DERIVATIVE | THE UPJOHN COMPANY (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0352269-A1 | ANTIBIOTIC SULFONYLAMINOCARBONYL ACTIVATED $g(b)-LACTAMS | THE UPJOHN COMPANY (US) | 1990-01-31 | — | — | EP | disclosed |
| EP-0344197-A1 | NOVEL N-1 SUBSTITUTED BETA-LACTAMS AS ANTIBIOTICS. | UPJOHN CO (US) | 1989-12-06 | — | — | EP | disclosed |
| WO-1989000569-A1 | THERAPEUTICALLY USEFUL beta-LACTAMS | THE UPJOHN COMPANY (US) | 1989-01-26 | — | — | WO | disclosed |
| EP-0281289-A1 | Antibiotic sulfonylaminocarbonyl activated beta-lactams | THE UPJOHN COMPANY (US) | 1988-09-07 | — | — | EP | disclosed |
| WO-1988006588-A1 | ANTIBIOTIC SULFONYLAMINOCARBONYL ACTIVATED beta-LACTAMS | THE UPJOHN COMPANY (US) | 1988-09-07 | — | — | WO | disclosed |
| WO-1988006587-A1 | ANTIBIOTIC beta-LACTAMS CONTAINING A PYRIDONE CARBOXYLIC ACID OR ACID DERIVATIVE | THE UPJOHN COMPANY (US) | 1988-09-07 | — | — | WO | disclosed |
| WO-1988006156-A1 | NOVEL N-1 SUBSTITUTED beta-LACTAMS AS ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1988-08-25 | — | — | WO | disclosed |